Janus Henderson Group PLC Boosts Stake in Krystal Biotech, Inc. $KRYS

Janus Henderson Group PLC increased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 21.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 266,659 shares of the company’s stock after acquiring an additional 47,219 shares during the period. Janus Henderson Group PLC’s holdings in Krystal Biotech were worth $68,879,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. UMB Bank n.a. lifted its holdings in Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the period. Optimize Financial Inc boosted its position in shares of Krystal Biotech by 1.4% during the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock worth $704,000 after purchasing an additional 40 shares in the last quarter. Perigon Wealth Management LLC grew its stake in shares of Krystal Biotech by 0.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after purchasing an additional 41 shares during the period. Regal Investment Advisors LLC grew its stake in shares of Krystal Biotech by 1.0% during the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after purchasing an additional 44 shares during the period. Finally, Torray Investment Partners LLC grew its stake in shares of Krystal Biotech by 0.4% during the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after purchasing an additional 47 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $341.12 on Friday. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of 45.60 and a beta of 0.50. Krystal Biotech, Inc. has a fifty-two week low of $130.50 and a fifty-two week high of $382.54. The stock’s fifty day moving average is $339.70 and its two-hundred day moving average is $296.28.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. As a group, sell-side analysts forecast that Krystal Biotech, Inc. will post 7.31 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the transaction, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 26,642 shares of company stock worth $8,243,923. 13.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Jefferies Financial Group restated a “buy” rating and set a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. TD Cowen increased their target price on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 1st. Finally, Citigroup lifted their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $360.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.